CSPC PHARMA's SYH2082 injection approved for clinical use in the United States
CSPC PHARMA (01093.HK) announced that the GLP-1/GIP receptor dual agonist long-acting injection (SYH2082 injection) developed by the group has been approved by the U.S. Food and Drug Administration to conduct clinical trials in the United States.
The group stated that SYH2082 selectively activates the cAMP pathway, reduces β-arrestin recruitment, thereby decreasing receptor internalization and desensitization, enhancing efficacy and prolonging duration of action. At the same time, SYH2082 combines long half-life modification platform technology and long-acting formulation platform technology, aiming to achieve sustained weight loss during the dosing interval
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments